Baillie Gifford & Co
CSTL icon

Baillie Gifford & Co’s Castle Biosciences CSTL Stock Holding History

Baillie Gifford & Co’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-225
Closed -$5.11K – 331
2023
Q1 		$5.11K Hold
225
– – ﹤0.01% 415
2022
Q4 		$5.3K Hold
225
– – ﹤0.01% 444
2022
Q3 		$6K Hold
225
– – ﹤0.01% 434
2022
Q2 		$5K Hold
225
– – ﹤0.01% 447
2022
Q1 		$10K Hold
225
– – ﹤0.01% 432
2021
Q4 		$10K Hold
225
– – ﹤0.01% 447
2021
Q3 		$15K Buy
225
+25
+13% +$1.76K ﹤0.01% 402
2021
Q2 		$15K Buy
+200
New +$13.2K ﹤0.01% 383

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co's CSTL Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 225 shares — an estimated $5.11K sold.

Baillie Gifford & Co first reported a position in CSTL in Q2 2021 and held it in 8 quarters. The position peaked at $15K in Q3 2021. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 225 Castle Biosciences shares in Q2 2023, an estimated $5.11K.
  • Baillie Gifford & Co first reported a position in Castle Biosciences in Q2 2021 and held it in 8 quarters.
  • Baillie Gifford & Co's Castle Biosciences position peaked at $15K in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.